BioTech Mag Search: Pharmaceutical
Neurocrine Inks $50M Xenon Pharma Deal to Expand Into Epilepsy
8 days ago - By Xconomy
Neurocrine Biosciences is paying $30 million cash and taking a $20 million equity stake in Xenon Pharmaceuticals to license a clinical-stage epilepsy drug and collaborate on other potential treatments for the seizure-causing brain disorder. The Xenon deal is the second one San Diego-based Neurocrine has struck this year in a bid to expand the landscape of neurological disorders for which it can offer treatment. For its $50 million, Neurocrine gets the rights to Xenon's experimental treatment for a rare, hereditary form of early-onset epilepsy caused by mutations to the gene SCN8A...
Read more ...
Search by Tags
Pharmaceutical Pharma Drug Brain Biosciences Drugs Neurology Pharmaceuticals Clinical Gene Genes National blog main San Diego San Diego blog main San Diego top stories AbbVie Biotech Clinical trials Deals Epilepsy FDA Financing Licensing Life Sciences Neurocrine Biosciences Pipeline Research collaboration Xenon Pharmaceuticals
The headlines of BioTech Mag
2nd International Conference on Generic Drugs and Biosimilars
2nd International Conference on Generic Drugs and Biosimilars
2nd International Conference on Generic Drugs and Biosimilars
2nd International Conference on Generic Drugs and Biosimilars
Perceptive Unveils New $210M Fund to Invest in Early-Stage Biotechs
Perceptive Advisors, an investment firm with a long track record of life science investing across all points of development, is now stepping up to pump money into companies at...
Eying Cancer Combos, Sanofi to Splash Out $2.5B on San Diego's Synthorx
Synthorx is working to design new cytokine therapies for cancer using an “extended” genetic alphabet that could help avoid the shortcomings associated with earlier versions...
Flagship's Cellarity Aims to Advance Cell Behavior-Based Therapeutics
The latest startup to emerge from Flagship Pioneering aims to change drug discovery by starting the process with a clear understanding of cell behavior. Cellarity-like many...
KalVista Pharma Eye Drug Partnered With Merck Flunks Phase 2 Test
A KalVista Pharmaceuticals eye drug at the center of a research collaboration with Merck has failed a mid-stage clinical trial. KalVista developed its drug, KVD001, to treat...
Zentalis Steps Out With $147M Raised to Develop “Tried and True” Small Molecules
Zentalis Pharmaceuticals is banking on small molecules for cancer-leaving the “cool technologies” aside for a “tried and true” approach, says the CEO, who wants to let the...
Scripps Research, AbbVie Expand Drug Discovery Deal Beyond Cancer
The Scripps Research Institute and AbbVie have agreed to broaden an existing drug discovery agreement focused on cancer cell therapies to now encompass treatments for other...
Aurinia Plans FDA Filing After Lupus Nephritis Drug Hits Phase 3 Goals
Aurinia shares spiked last week after voclosporin, an immunosuppressant being tested in patients with lupus nephritis, met its primary and secondary endpoints in a Phase 3...
Artificial Pancreas Keeps Patients Healthier: A Perspective
The late Mayo endocrinologists Russell Wilder, M.D., and Randall Sprague, M.D., would be smiling today at the news for patients with diabetes. Much of their lives and careers...
Merck Makes a Big Blood Cancer Bet With $2.7B Deal for ArQule
Merck is acquiring cancer drug developer ArQule for $2.7 billion , a cash deal that brings it a promising early-stage compound that could challenge a blockbuster leukemia drug...
AstraZeneca Taps Gatehouse Bio to Identify Potential Drug Targets
After joining AstraZeneca's Boston Bio Hub incubator last year, Gatehouse Bio is now teaming up with the pharma company to identify potential drug targets in respiratory and...